Drug Trial News

RSS

Study: Personalized neoantigen vaccine stimulates strong anti-tumor response in melanoma patients

A personal cancer treatment vaccine that targets distinctive "neoantigens" on tumor cells has been shown to stimulate a potent, safe, and highly specific immune anti-tumor response in melanoma patients, report scientists from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.

5 Jul 2017

Clinical trial of immunotherapy shows promising results for patients with melanoma brain tumors

Two years ago, when Kathy Roberts was 54, she started having pain in her ankle. She ignored it. Then it became swollen, and she had more and more trouble walking. So she went to a series of doctors trying to figure out the problem.

27 Jun 2017

Experimental drug benefits some patients with advanced kidney cancer

Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.

24 Jun 2017

Defining patient centricity

"Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family.”

20 Jun 2017

First-ever clinical study for effective treatment of mycetoma begins in Sudan

The first-ever double-blind, randomized clinical trial for an effective treatment for the severely neglected disease mycetoma has enrolled its first patient at the Mycetoma Research Centre in Khartoum, Sudan.

19 Jun 2017

Pfizer initiates Phase 1 trial of investigational GBS vaccine

Pfizer Inc. today announced that it has started a Phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine designed to help protect against Group B Streptococcus (GBS) infection.

19 Jun 2017

New chemoprevention trial hopes to stop dangerous lesions from progressing to cancer

New treatments have extended the lives of many lung cancer patients. However, even better than treating lung cancer would be preventing it from developing in the first place.

15 Jun 2017

UNC researchers evaluate investigational medication for treatment of postpartum depression

Researchers at the University of North Carolina School of Medicine announced the publication of results from a multi-site phase 2 clinical trial with brexanolone, an investigational medication, in the treatment of severe postpartum depression.

13 Jun 2017

Clinical study shows new mechanism that BCG vaccine uses to reverse advanced type 1 diabetes

Interim results from a FDA-approved clinical trial testing the generic vaccine bacillus Calmette-Guérin (BCG) to reverse advanced type 1 diabetes are being presented at the 75th Scientific Sessions of the American Diabetes Association.

12 Jun 2017

Combination treatment found to effective in patients with tophaceous gout

The drug lesinurad in combination with febuxostat was better at lowering blood levels of urate than febuxostat alone in a phase III clinical trial of 324 patients with tophaceous gout.

9 Jun 2017

Adding a second HER2-targeted treatment may improve outcomes for some women with breast cancer

A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests adding a second HER2 targeted medicine, pertuzumab (Perjeta), to standard of care trastuzumab (Herceptin) after surgery may help, although the benefit is modest.

6 Jun 2017

Findings point to potential new treatment for people with newly diagnosed EGFR-positive NSCLC

Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC).

5 Jun 2017

New targeted oral therapy results in durable responses across many kinds of cancer

Scientists may have developed the first targeted, oral, tumor-type agnostic therapy - a cancer medicine that works comparably well across many kinds of cancer, regardless of patient age. In clinical trials of adults and children with 17 different types of advanced cancer, larotrectinib treatment resulted in responses in 76% of patients.

5 Jun 2017

Positive results for AstraZeneca’s PARP inhibitor Lynparza in advanced breast cancer

A new study has shown that AstraZeneca's Lynparza (olaparib) can significantly slow the progress of breast cancer that is caused partially due to mutations of the culprit gene called BRCA. BRCA gene mutations are responsible for around 3% of all breast cancers. These cases of the disease that have a basis in the gene are notoriously difficult to treat and women who are tested positive for this gene may even opt for removal of their breasts before even the cancer strikes. Noted actress Angelina Jolie went for a similar prophylactic mastectomy.

5 Jun 2017

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

A clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%.

5 Jun 2017

Immunotherapy combination offers new hope for women with early stage triple negative breast cancer

A Yale Cancer Center clinical trial combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer disclosed a 71% pathologic complete response to the combination treatment in the initial phase I trial.

2 Jun 2017

Early study of experimental vaccine shows escalating immune response in patients with sarcoma

The critical component of an experimental vaccine led to an escalating immune response in patients with sarcoma, an indicator of its potential anti-cancer effects.

2 Jun 2017

Common acne medication can slow progress of relapsing-remitting MS, trial shows

A Canadian clinical trial led by researchers at the University of Calgary's Hotchkiss Brain Institute, at the Cumming School of Medicine, shows that minocycline, a common acne medication, can slow the progress of relapsing-remitting multiple sclerosis (MS) in people who have recently experienced their first symptoms.

1 Jun 2017

Experimental drug increases progression-free survival in pancreatic cancer patients, clinical trial shows

By adding an experimental drug to a standard chemotherapy regimen, a subset of patients with metastatic pancreatic cancer had a significantly longer period before the cancer progressed as compared with those who received the standard treatment, according to a Phase 2 clinical trial led by an investigator at Fred Hutchinson Cancer Research Center.

1 Jun 2017

Phase 2 clinical study examines Alzheimer's disease drug to treat adults with Down syndrome

A phase 2 clinical trial in young adults with Down syndrome of a drug being investigated for the treatment of Alzheimer's disease supports further investigation of its potential.

1 Jun 2017

Drug Trial News

Study: Personalized neoantigen vaccine stimulates strong anti-tumor response in melanoma patients

Clinical trial of immunotherapy shows promising results for patients with melanoma brain tumors

Experimental drug benefits some patients with advanced kidney cancer

Defining patient centricity

First-ever clinical study for effective treatment of mycetoma begins in Sudan

Pfizer initiates Phase 1 trial of investigational GBS vaccine

New chemoprevention trial hopes to stop dangerous lesions from progressing to cancer

UNC researchers evaluate investigational medication for treatment of postpartum depression

Clinical study shows new mechanism that BCG vaccine uses to reverse advanced type 1 diabetes

Combination treatment found to effective in patients with tophaceous gout

Adding a second HER2-targeted treatment may improve outcomes for some women with breast cancer

Findings point to potential new treatment for people with newly diagnosed EGFR-positive NSCLC

New targeted oral therapy results in durable responses across many kinds of cancer

Positive results for AstraZeneca’s PARP inhibitor Lynparza in advanced breast cancer

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

Immunotherapy combination offers new hope for women with early stage triple negative breast cancer

Early study of experimental vaccine shows escalating immune response in patients with sarcoma

Common acne medication can slow progress of relapsing-remitting MS, trial shows

Experimental drug increases progression-free survival in pancreatic cancer patients, clinical trial shows

Phase 2 clinical study examines Alzheimer's disease drug to treat adults with Down syndrome

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News